Lakefront Biotherapeutics LKFT
Lakefront Biotherapeutics (Nasdaq: LKFT) is an immunology/inflammation drug developer. Its lead program, Gamgertamig (OM336), is in Phase 2 for Autoimmune cytopenias (ITP, AIHA) and seropositive autoimmune diseases (myositis, Sjogren's, pemphigus). Its next catalyst on record is Gamgertamig: Expected entry into registrational studies (Gilead-led) (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Gamgertamig — Expected entry into registrational studies (Gilead-led) (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Gamgertamig (OM336), BCMAxCD3 T-cell engager | ITP, AIHA, pemphigus, myositis, Sjogren's; Phase 1b studies NCT07083960 and NCT07229144 enrolling; company describes as 'currently in Phase 2 studies'; FDA Fast Track/Orphan (AIHA, ITP), Orphan (pemphigus) | antibody | Phase 2 |
| GLPG3667 (TYK2 inhibitor) | Dermatomyositis and SLE; two Phase 2 studies reported topline ('Phase 3-enabling'); strategic options under evaluation | small molecule | Phase 2 |
| Cell therapy programs (CAR-T) | Oncology; wind-down initiated January 2026, expected substantially complete by end Q3 2026 | cell therapy | Phase 2 |
| Three preclinical autoimmune programs in-licensed from Ouro | Autoimmune diseases; Gilead opt-in after clinical proof-of-concept | unclear | Pre-clinical |
Recent results and decisions
- Aug 10, 2026missed Phase 2 GALACELA study of GLPG3667 in SLE completed; did not meet the 32-week primary endpoint or the comparable 48-week secondary endpoint, with favorable safety at 48 weeks.
The Phase 2 GALACELA study in systemic lupus erythematosus (SLE) has completed with continued favorable safety at 48 weeks; the trial did not meet the 32-week primary endpoint and comparable 48-week secondary endpoint.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.